Cannabis Science Negotiates Commercialization Deal to Bring Cannabis Science Brand Formulations Immediately into the California Market

December 14, 2011

DENVER--(BUSINESS WIRE)-- Cannabis Science, Inc. (OTCBB:CBIS.ob), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce it has entered final negotiations to bring Cannabis Science Brand of Pharmaceutical products into California.

Following the release of our cannabis extract based formulation in Colorado, and international anecdotal cases reports from patients with Cancer, Cannabis Science is finalizing agreements to expand our business into California.

This new strategic partnership would allow Cannabis Science to better satisfy the demand for its formulations by making them available to more than 1.4 million cancer patients in California. This strategic alliance also brings to the table significant resources for Cannabis Science in California including laboratories for quality assurance and testing, an educational platform to distribute information about the science of cannabis (everything on should know from the seed to sale) Additionally, as part of the deal we will acquire organically produced strains for our scientific medicinal formulations. Furthermore, if California goes fully legal in 2014, it should bring down production costs and savings could be passed along to the patients.

Dr. Melamede stated “ For too long patients have requested our formulations, as a result we have gathered anecdotal reports thru personal testimonials that have demonstrated to us the need for our products in California. We look forward to bringing these products thru the California regulatory system in the near future. Similarly, as the laws allow, we intend to bring our products to other medical marijuana states through additional strategic mergers, acquisitions, and partnerships.

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science
Dr. Robert Melamede, President
www.cannabisscience.com
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
or
Investor Relations
Robert Kane
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
561.234.6929